Search research articles
Contact Us
Filters
Showing results (171-180 of 1,137) with videos related to
Page
of 114
Sort By:
Critical Pathways in Cardiology
|
March 11, 2010
The use and limitations of unfractionated heparin
Amar Krishnaswamy, A Michael Lincoff, Christopher P Cannon
The New England Journal of Medicine
|
July 9, 2005
Intensive lipid lowering with atorvastatin in coronary disease
Christopher P Cannon, Sabina A Murphy, Eugene Braunwald
Annals of Internal Medicine
|
September 12, 1998
The antiplatelet effects of ticlopidine and clopidogrel
P J Sharis, C P Cannon, J Loscalzo
Methods in Molecular Biology (Clifton, N.J.)
|
June 25, 2011
Construction, expression, and purification of chimeric protein reagents based on immunoglobulin fc regions
John P Cannon, Marci O'Driscoll, Gary W Litman
Journal of the American College of Cardiology
|
March 27, 2010
High-density lipoprotein and coronary heart disease: current and future therapies
Pradeep Natarajan, Kausik K Ray, Christopher P Cannon
European Journal of Clinical Pharmacology
|
January 1, 1983
Nifedipine in the treatment of hypertension
F Brennan, M Flanagan, S Blake, et al.
Clinical Cardiology
|
June 24, 2005
Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial
James L Januzzi, Jacqueline Buros, Christopher P Cannon, et al.
The American Journal of Cardiology
|
November 28, 2006
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Kausik K Ray, Christopher P Cannon, Peter Ganz
Expert Opinion on Drug Safety
|
September 28, 2010
Bleeding complications of unfractionated heparin
Amar Krishnaswamy, A Michael Lincoff, Christopher P Cannon
International Journal of Clinical Practice
|
June 20, 2007
Recent trials of lipid lowering
K K Ray, C P Cannon, E Braunwald
Page
of 114
Search research articles
Search
Showing results (171-180 of 1,137) with videos related to
Sort By:
Page
of 114
Critical Pathways in Cardiology
|
March 11, 2010
The use and limitations of unfractionated heparin
Amar Krishnaswamy, A Michael Lincoff, Christopher P Cannon
The New England Journal of Medicine
|
July 9, 2005
Intensive lipid lowering with atorvastatin in coronary disease
Christopher P Cannon, Sabina A Murphy, Eugene Braunwald
Annals of Internal Medicine
|
September 12, 1998
The antiplatelet effects of ticlopidine and clopidogrel
P J Sharis, C P Cannon, J Loscalzo
Methods in Molecular Biology (Clifton, N.J.)
|
June 25, 2011
Construction, expression, and purification of chimeric protein reagents based on immunoglobulin fc regions
John P Cannon, Marci O'Driscoll, Gary W Litman
Journal of the American College of Cardiology
|
March 27, 2010
High-density lipoprotein and coronary heart disease: current and future therapies
Pradeep Natarajan, Kausik K Ray, Christopher P Cannon
European Journal of Clinical Pharmacology
|
January 1, 1983
Nifedipine in the treatment of hypertension
F Brennan, M Flanagan, S Blake, et al.
Clinical Cardiology
|
June 24, 2005
Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial
James L Januzzi, Jacqueline Buros, Christopher P Cannon, et al.
The American Journal of Cardiology
|
November 28, 2006
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Kausik K Ray, Christopher P Cannon, Peter Ganz
Expert Opinion on Drug Safety
|
September 28, 2010
Bleeding complications of unfractionated heparin
Amar Krishnaswamy, A Michael Lincoff, Christopher P Cannon
International Journal of Clinical Practice
|
June 20, 2007
Recent trials of lipid lowering
K K Ray, C P Cannon, E Braunwald
Page
of 114